291 related articles for article (PubMed ID: 30529714)
1. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
[No Abstract] [Full Text] [Related]
2. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
[No Abstract] [Full Text] [Related]
3. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
Di Leo E; Calogiuri G; Macchia L; Nettis E
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
[No Abstract] [Full Text] [Related]
4. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab for chronic urticaria in children younger than 12 years.
Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
[No Abstract] [Full Text] [Related]
6. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
[No Abstract] [Full Text] [Related]
7. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
Dortas Junior S; Azizi G; Valle S
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
[No Abstract] [Full Text] [Related]
9. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
Maurer M; Kolkhir P; Moñino-Romero S; Metz M
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
[No Abstract] [Full Text] [Related]
10. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
11. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
Cho YT; Fu KT; Yang CW; Chu CY
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
[No Abstract] [Full Text] [Related]
12. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
Hayama K; Fujita H; Asai-Sato M; Kawana K; Terui T
Eur J Dermatol; 2021 Feb; 31(1):100-101. PubMed ID: 33459258
[No Abstract] [Full Text] [Related]
13. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
[No Abstract] [Full Text] [Related]
14. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
Casale TB; Murphy TR; Holden M; Rajput Y; Yoo B; Bernstein JA
J Allergy Clin Immunol Pract; 2019; 7(7):2487-2490.e1. PubMed ID: 31034999
[No Abstract] [Full Text] [Related]
15. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
Ayhan E; Öztürk M; An İ; Bekçİbaşi M
Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
[No Abstract] [Full Text] [Related]
16. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.
Spekhorst LS; van den Reek JMPA; Knulst AC; Röckmann H
Allergy; 2019 Jun; 74(6):1185-1187. PubMed ID: 30593687
[No Abstract] [Full Text] [Related]
17. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
Bae Y; Kang SH; Park JO; Park GH; Choi JH
Allergol Int; 2020 Apr; 69(2):304-306. PubMed ID: 31767272
[No Abstract] [Full Text] [Related]
18. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
Belbezier A; Boccon-Gibod I; Bouillet L
Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
[No Abstract] [Full Text] [Related]
19. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
20. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China.
Chen YD; Maurer M; Yu M; Tu P; Zhao ZT
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240
[No Abstract] [Full Text] [Related]
[Next] [New Search]
